Foundation model cascades enable zero-shot microscopy image analysis for cell therapy manufacturing
Year: 2026
Type: article
Abstract: BACKGROUND AIMS: The scalable manufacturing of cell therapies creates a significant need for robust process analytical technologies, where automated analysis of noninvasive microscopy images offers a powerful method for monitoring critical quality attributes. However, conventional machine-learning models are often bottlenecked by extensive data labeling and poor generalizability across different batch effects. To overcome these limitations, we introduce a foundational model cascade for the zero-shot analysis of microscopy images. METHODS: In the first stage, a multimodal large language model (LLM) detects anomalies, and anomalous images immediately trigger an alert. Otherwise, the segment anything model performs exhaustive instance segmentation, and the detected objects are classified by the LLM to estimate cell counts and viability. RESULTS: This unified, zero-shot approach delivers robust anomaly detection together with quantitative measures of cell count and health, without any task-specific fine-tuning. CONCLUSIONS: By combining pre-trained foundation models in a complementary cascade, our method provides a generalizable solution for real-time process monitoring and feedback control, paving the way for more scalable and automated cell therapy manufacturing.
Source: Cytotherapy
Language: English
Subfield: Biophysics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,300
Funders: National Science Foundation, Burroughs Wellcome Fund, California Institute for Regenerative Medicine, Gateway for Cancer Research, Research Institute, Georgia Institute of Technology, Georgia Institute of Technology, Google, Billi and Bernie Marcus Foundation, National Institutes of Health, U.S. Food and Drug Administration, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Awards: G1094731811, G5811795523, G5996989908, G6898148451, Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma, T32 CTEng (Cellular and Tissue Engineering) Training Program, Accessible label-free optical microscopy with quantitative molecular and functional contrast
OpenAlex ID: W7127410070
